The efficacy and tolerability of ezetimibe in cardiac transplant recipients taking cyclosporin

Transplantation

Volumn 87, Issue 5, 2009, Pages 771-775

  Shaw, Steven M ^a,b   Chaggar, Parminder ^a   Ritchie, James ^a   Shah, Mohammed K H ^a   Baynes, Anna C ^a   O'Neill, Nicola ^a   Fildes, James E ^a   Yonan, Nizar ^a   Williams, Simon G ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

Ezetimibe; Hyperlipidaemia; Transplantation; Vasculopathy

Indexed keywords

ATORVASTATIN; AZATHIOPRINE; CYCLOSPORIN; CYCLOSPORIN A; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAVASTATIN; PREDNISOLONE; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; AZETIDINE DERIVATIVE; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; IMMUNOSUPPRESSIVE AGENT; LOW DENSITY LIPOPROTEIN; PLACEBO;

ABDOMINAL CRAMP; ADD ON THERAPY; ADULT; AGED; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NECK PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BLOOD; DOUBLE BLIND PROCEDURE; DRUG EFFECT; IMMUNOLOGY; MIDDLE AGED; SAFETY;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL; CYCLOSPORINE; DOUBLE-BLIND METHOD; FEMALE; HEART TRANSPLANTATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PLACEBOS; SAFETY;

EID: 65649116901     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318198d7d0     Document Type: Article

References (20)

1. Wenke K. Management of hyperlipidaemia associated with heart transplantation. Drugs 2004; 64: 1053.
2. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth official adult heart transplant report-2007. J Heart Lung Transplant 2007; 26: 769.
3. Schmauss D, Weis M. Cardiac allograft vasculopathy: Recent developments. Circulation 2008; 117: 2131.
4. Lopez MM, Valenzuela JE, Alvarez FC, et al. Long-term problems related to immunosuppression. Transpl Immunol 2006; 17: 31.
5. Ballantyne CM, Podet EJ, Patsch WP, et al. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 1989; 262: 53.
6. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621.
7. Wenke K, Meiser B, Thiery J, et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation 2003; 107: 93.
8. Carrier M, Rivard M, Kostuk W, et al. The Canadian Study of Cardiac Transplantation. Atherosclerosis. Investigators of the CASCADE Study. Can J Cardiol 1999; 15: 1337.
9. Ballantyne CM, Bourge RC, Domalik LJ, et al. Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry. Am J Cardiol 1996; 78: 532.
10. Sewright KA, Clarkson PM, Thompson PD. Statin myopathy: Incidence, risk factors, and pathophysiology. Curr Atheroscler Rep 2007; 9: 389.
11. Akhlaghi F, McLachlan AJ, Keogh AM, et al. Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. Br J Clin Pharmacol 1997; 44: 537.
12. Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003; 163: 553.
13. Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002; 90: 1092.
14. Pearson TA, Denke MA, McBride PE, et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: The ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005; 80: 587.
15. Bays H. Ezetimibe. Expert Opin Investig Drugs 2002; 11: 1587.
16. Konstandin MH, Blessing E, Doesch A, et al. Ezetimibe effectively lowers LDL-cholesterol in cardiac allograft recipients on stable statin therapy. Clin Transplant 2008; 22: 639.
17. Quarta CC, Potena L, Grigioni F, et al. Safety and efficacy of ezetimibe with low doses of simvastatin in heart transplant recipients. J Heart Lung Transplant 2008; 27: 685.
18. Bergman AJ, Burke J, Larson P, et al. Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects. J Clin Pharmacol 2006; 46: 321.
19. Bergman AJ, Burke J, Larson P, et al. Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients. J Clin Pharmacol 2006; 46: 328.
20. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431.